First Foundation Advisors Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Foundation Advisors grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 168.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,457 shares of the medical research company's stock after purchasing an additional 914 shares during the quarter. First Foundation Advisors' holdings in Thermo Fisher Scientific were worth $725,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. S&CO Inc. lifted its holdings in shares of Thermo Fisher Scientific by 7.5% in the first quarter. S&CO Inc. now owns 41,872 shares of the medical research company's stock worth $20,835,000 after buying an additional 2,911 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $4,042,000. Geneos Wealth Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 16.9% in the first quarter. Geneos Wealth Management Inc. now owns 4,969 shares of the medical research company's stock worth $2,473,000 after buying an additional 718 shares in the last quarter. N.E.W. Advisory Services LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $110,000. Finally, TCTC Holdings LLC lifted its holdings in shares of Thermo Fisher Scientific by 36.8% in the first quarter. TCTC Holdings LLC now owns 186 shares of the medical research company's stock worth $93,000 after buying an additional 50 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $4.94 during trading hours on Friday, reaching $462.74. The company had a trading volume of 2,756,840 shares, compared to its average volume of 2,531,924. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The firm has a market cap of $174.68 billion, a PE ratio of 26.76, a price-to-earnings-growth ratio of 2.55 and a beta of 0.77. The business's 50 day moving average price is $419.50 and its 200-day moving average price is $468.31. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on TMO. Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, UBS Group lifted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.